BRAF and melanoma: Firstly, we examined the baseline phenotype of two BRAF-mutated human melanoma cell lines (A375P and FO-1P) and assessed the molecular signature changes after 4–5 months of treatment with increasing concentrations of the second-generation BRAF inhibitor dabrafenib and of the third-generation pan-RAF inhibitor AZ628.